News

Alzheimer's treatment 'benefits patients with severe disease'

05-Dec-08

Taking the cholinesterase inhibitor galantamine has been shown for the first time to improve cognitive function in patients with severe Alzheimer's disease, according to UK research.

Currently, the drug is only prescribed to patients with mild to moderate Alzheimer's, and stopped when their condition deteriorates to the severe stage.

For this latest study, the researchers randomly assigned 407 patients with severe Alzheimer's who were living in a nursing home to receive galantamine, 24mg daily, or placebo for six months.

Overall, the researchers found that patients who were given galantamine had improved cognitive function, particularly memory and the ability to carry out motor performance tasks.

However, the carers who were looking after the patients reported that those on galantamine showed no improvement in their ability to undertake everyday tasks, compared with the patients on placebo.

The researchers, from the University of Manchester, said: 'The data shows there are untreated patients with severe Alzheimer's disease in nursing homes who could benefit from starting treatment with galantamine.'

But in an editorial, Dr Martin Farlow, from Indiana University, warned that the 'clinical usefulness of galantamine has still not been proven in this population'.

sanjay.tanday@haymarket.com

Comment below and tell us what you think

Comments

Only registered users may comment. Log in now or register for a free account.

There are problems with your form submission.

Please review the errors shown below.



Forgot your password?

Quick search - use * for an abbreviated search, eg nico*

 
 

Healthcare Republic Forums

 

Quick search - use * for an abbreviated search, eg nico*

 
 

Latest Clinical Articles

Abnormal uterine bleeding

Contributed by Mr Antonio V Antoniou, consultant gynaecologist and lead in minimal access surgery an... Read more

Chronic low back pain

Dr Mark Ritchie, GPSI in pain management, Morriston, Swansea Read more

Acute and sub-acute back pain

Contributed by Dr Mark Ritchie, GPSI in pain management, Morriston, Swansea Read more

Show all clinical articles

MIMS Product News

New drug - Stelara

Janssen-Cilag has launched Stelara for the treatment of moderate to severe plaque psoriasis where ot... Read more

New high-strength nicotine patch

Nicorette Invisipatch is the latest addition to the range of available nicotine replacement therapy ... Read more

Prolonged-release aspirin

Flamasacard, a prolonged-release formulation of aspirin, for secondary prophylaxis after a first cor... Read more

Jobs